Exicure (NASDAQ:XCUR) is a pioneering biotechnology firm deeply engaged in the design and development of therapeutics based on its proprietary spherical nucleic acid (SNA™) technology. These advanced therapeutics have a wide range of applications, including gene regulation and immunotherapy. Exicure's main goal is to harness the power of SNA to unlock new possibilities in the treatment of diseases with genetic origins or for which traditional approaches have been inadequate. The company focuses on advancing its pipeline of innovative treatments through rigorous clinical trials, with the aim of addressing unmet medical needs and improving patient care. By pushing the boundaries of science and technology, Exicure strives to make a significant impact on medicine and healthcare.